Salvage Liver Transplantation for Patients with Recurrent
Hepatocellular Carcinoma after Curative Resection
LinWei Wu1., AnBin Hu1., Ngalei Tam1., JianWei Zhang2, Min Lin2, ZhiYong Guo1*, XiaoShun He1*
1Organ Transplant Center of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 2 Zhongshan Medical School of Sun Yat-sen University, Guangzhou,
China
Abstract
Objective: To summarize the experience with salvage liver transplantation (SLT) for patients with recurrent hepatocellular
carcinoma (HCC) after primary hepatic resection in a single center.
Methods: A total of 376 adult patients with HCC underwent orthotopic liver transplantation (OLT) at Organ Transplantation
Center, the First Affiliated Hospital of Sun Yat-sen University, between 2004 and 2008. Among these patients, 36 underwent
SLT after primary liver curative resection due to intrahepatic recurrence. During the same period, one hundred and fortyseven patients with HCC within Milan criteria underwent primary OLT (PLTW group), the intra-operative and post-operative
parameters were compared between these two groups. Furthermore, we compared tumor recurrence and patient survival
of patients with SLT to 156 patients with HCC beyond Milan criteria (PLTB group). Cox Hazard regression was made to
identify the risk factors for tumor recurrence.
Results: The median interval between initial liver resection and SLT was 35 months (1–63 months). The intraoperative blood
loss (P,0.05) and transfusion volume (P,0.05) were larger in the SLT group than in the PLTW group. The operation time
was longer in the SLT group (P,0.05). The post-operative complications incidence, tumor recurrence rate, patients’ survival
rate, and tumor-free survival rate were comparable between these two groups (all P.0.05). When compared to those
patients with HCC beyond Milan criteria undergoing primary OLT, patients undergoing SLT achieved a better survival and a
lower tumor recurrence. Cox Proportional Hazards model showed that vascular invasion, including macrovascular and
microvascular invasion, as well as AFP level .400 IU/L were risk factors for tumor recurrence after LT.
Conclusions: In comparison with primary OLT, although SLT is associated with increased operation difficulties, it provides a
good option for patients with HCC recurrence after curative resection.
Citation: Wu L, Hu A, Tam N, Zhang J, Lin M, et al. (2012) Salvage Liver Transplantation for Patients with Recurrent Hepatocellular Carcinoma after Curative
Resection. PLoS ONE 7(7): e41820. doi:10.1371/journal.pone.0041820
Editor: Mercedes Susan Mandell, University of Colorado, United States of America
Received February 9, 2012; Accepted June 26, 2012; Published July 26, 2012
Copyright:  2012 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National High Technology Research and Development Program of China (863 Program) (2012AA021008), the Key
Clinical Project from the Ministry of Health (2010159), the National Natural Science Foundation of China (30972951, 81102244, 81102245, and 81170448), the
Special Fund for science research by Ministry of Health (201002004), the Research Fund for the Doctoral Program of Higher Education of China by Ministry of
Education (20100171110063 and 20110171120077), the Science and Technology Planning Key Clinical Project of Guangdong Province (2011A030400005), Science
and Technology Planning Project of Guangdong Province (2011B0318000099), Medical Scientific Research Foundation of Guangdong Province (B2011072) and
Project by Division of Medical Service Management of Ministry of Health (2010). The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: gdtrc@126.com (XH); rockyucsf1981@126.com (ZG)
. These authors contributed equally to this work.
Introduction
In China mainland, the incidence of hepatocellular carcinoma
(HCC) is increasing, and it is the third leading cause of cancer
mortality [1]. Orthotopic liver transplantation (OLT) remains the
most effective treatment for patients with small HCC. However,
due to organ shortage, economic or conceptional constraints,
only a small population of such patients could receive a
transplant. Hepatic resection (HR) remains a more reasonable
choice for the vast majority of such patients although they might
face a higher risk of tumor recurrence or liver function
deterioration. However, for those patients with HCC recurrence
after hepatic resection, 80% might be rescued by means of liver
transplant [2,3]. The concept of liver transplant performed after
HCC recurrence post HR, namely salvage liver transplantation
(SLT) has been introduced by Pietro E. Majno [2] in 2000.
Herein we retrospectively reviewed and compared the patient
survival and cancer recurrence rates between patients undergoing
SLT and primary OLT in our single center between 2004 and
2008.
Methods
Baseline characteristics of patients
From January 2004 to December 2008, 376 adult patients with
HCC received OLT at our center, including 296 males and 80
females (mean age, 50.8 years; age range, 18–75 years). The
patients who had tumor thrombosis of the main trunk of portal
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e41820

vein or hepatic vein (vena cava) (n = 19), and those who had ABO
incompatible match (n = 8), had split grafts (n = 6) and living
donors (n = 4) were excluded from this study.
Thirty-six patients received SLT after radical HR due to intrahepatic recurrence. All the 36 patients were included in the SLT
group. One hundred and forty-seven patients who received
primary OLT for HCC within Milan criteria were classified into
PLTW (primary OLT for HCC within Milan criteria) group. The
demographics and clinical data of the patients in the two groups
are shown in Table 1. There was no significant difference in preoperative baseline characteristics between the two groups. We also
compared the tumor recurrence and patients survival of SLT
group to 156 patients undergoing primary OLT for HCC beyond
Milan criteria (PLTB group), and the risk factors for tumor
recurrence was identified by Cox regression analysis.
All the participants received whole liver graft from deceased
donors. Different transplant techniques were performed, including 16 cases of classic OLT, 303 cases of modified piggyback
technique introduced by YM Wu [4] and 20 cases of classic
piggyback. The immunosuppressive regimens used included
double regimen (steroid and Tacrolimus or Cyclosporine (CsA))
and triple regimen (steroid, Tacrolimus or CsA, and Mycophenolate mofetil (MMF)). MMF was used in patients with a low
serum Tacrolimus concentration even under a relatively high
dose intake, and in those patients with hyperglycemia or renal
impairment during the early period post-transplantation. When
MMF was given, Tacrolimus was maintained in a lower tough
level. Liver function and blood concentration of immunosuppressants were monitored according to the protocols in our
center. Interleukin-2 receptor monoclonal antibody (Basiliximab)
induction was adopted in patients with high-risk factors, such
patients with age .60-year old, hypoalbuminemia, hepatorenal
syndrome and a model for end-stage liver disease (MELD) score
over 30. The interleukin-2 monoclonal antibody was adminisTable 1. Demographics of the patients.
SLT (n = 36) PLTW (n = 147) PLTB (n = 156) P value
Age (yr)
Mean 6 SD 49.4617.1 47.6615.8 51.1615.6 0.160
Median 48 (20–65) 49 (18–63) 46(22–68)
Gender(M/F) 27/9 106/31 118/38 0.775
HBV infection 35 (97.2) 144 (97.9) 149(95.5) 0.479
HCV infection 2 (5.5) 9 (6.1) 11(7.1) 0.921
ALT (IU/L) 110.5690.2 100.4684.8 122.7688.6 0.085
Sodium (mmol/L) 137.967.3 139.466.8 141.169.8 0.059
Albumin (mg/L) 36.9617.9 38.8620.9 34.9621.5 0.269
Creatinine (mmol/L) 95.5693.2 86.8695.3 105.1689.8 0.229
Bilirubin(mmol/L) 48.3639.6 57.2646.5 60.5637.3 0.282
INR 1.5960.48 1.6060.59 1.7560.62 0.065
MELD score 18.666.7 17.967.1 19.464.8 0.103
Liver cirrhosis 36(100%) 131(89.1%) 104(66.7%) ,0.001
Tumor demographics
Nodules numbers
solitary 21 86 40 ,0.001
#3 13 61 56 0.580
.3 2 0 60 ,0.001
Largest tumor size(mm) 48 50 130 0.465
AFP levels (IU/L)
,400 12 44 10 ,0.001
$400 24 103 146 ,0.001
Macro vascular invasion 0 0 37 ,0.001
Microvascular invasion 2 14 55 ,0.001
Pathologic characteristics
Poor differentiated 8 30 68 ,0.001
Well differentiated 28 117 88 ,0.001
Pre-transplant treatment
radiofrequency ablation 9 34 25 0.224
ethanol injection 6 25 30 0.860
TACE 3 14 18 0.777
Abbreviation: SLT, salvage liver transplantation; PLTW, primary liver transplantation for HCC within Milan criteria; PLTB, primary liver transplantation for HCC beyond
Milan criteria; TACE, transcatheter arterial chemoembolization.
doi:10.1371/journal.pone.0041820.t001
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41820

tered intraoperatively and on day 4 post-transplantation,
respectively. A dose of 500 mg steroid was administered during
operation. When induction therapy was used, Tacrolimus or CsA
was used from day 4 post-transplantation, and then was adjusted
according to plasma concentration. Prior to the study, the
protocol, which was in accordance with the ethical guidelines of
the 1975 Helsinki Declaration, was approved by the institutional
ethics committee of the First Affiliated Hospital of Sun Yat-sen
University. Written, informed consent was obtained from all
subjects.
Statistical analysis
All statistical analysis was performed using the Statistical
Package for Social Science 13.0 (SPSS, version 13.0; Chicago,
IL). Continuous variables were tested for normal distribution and
expressed as mean 6 standard deviation (SD) or median (range) as
appropriate. Categorical variables were compared by Pearson chisquared test and continuous variables were compared by Student’s
t-test. Univariate survival curves were estimated using the KaplanMeier method and compared by the log-rank test. Risk factors for
tumor recurrence were evaluated by a Cox Proportional Hazards
Table 2. Operative parameters and postoperative complications.
SLT (n = 36) PLTW (n = 147) t value or x
2 value P value
Donor liver cold ischemic time (h) 8.162.5 7.462.8 1.37 0.127
Anhepatic time (min) 39.665.2 38.366.9 1.06 0.268
Operative time (min) 340677 302681 2.54 0.024*
Application of arterial jump grafts 3 2 5.29 0.021
Roux-n-Y 4 3 6.47 0.011
Intraoperative bleeding volume (ml) 15606670 11806910 2.35 0.028*
Intraoperative transfusion volume (ml) 10606780 8206910 2.02 0.043*
Postoperative ICU time (h) 34612 29616 1.76 0.078
Primary graft nonfunction 0 0 – –
Delayed graft function 1 4 ,0.001 0.985
Intra-abdominal bleeding 0 4 1.001 0.317
Infections 2 14 0.571 0.450
Renal failure 1 3 0.073 0.786
Acute rejection 2 15 0.742 0.389
Biliary complications 2 14 0.571 0.450
Vascular complications 0 3 0.747 0.387
Recurrence of hepatitis 0 2 0.495 0.482
Abbreviation: SLT, salvage liver transplantation; PLTW, primary liver transplantation for HCC within Milan criteria; ICU, intensive care unit.
doi:10.1371/journal.pone.0041820.t002
Figure 1. (A) shows the cumulative survival rate between SLT group and PLTW group, a Log-Rank test showed P = 0.336. (B) shows the cumulative
survival rate between SLT group and PLTB group, a Log-Rank test showed P = 0.041. Abbreviation: SLT salvage liver transplantation, PLTW primary
liver transplantation within Milan criteria, PLTB primary liver transplantation beyond Milan criteria.
doi:10.1371/journal.pone.0041820.g001
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41820

model. For all analyses, P values,0.05 were considered statistically
significant.
Results
Implementation of SLT
Thirty-six patients, including 29 males and 7 females, received
SLT after radical HR due to intrahepatic recurrence. Sixteen
patients received primary right hemihepatectomy, 10 left hemihepatectomy and the others irregular hepatic segmentectomy pretransplantation. Before HR, 22 patients had single tumor nodule,
12 had 2 or 3 nodules, and only 2 had .3 tumor nodules. In all
patients, the tumors were located within a liver lobe without
macrovascular invasion. The post-operative pathologic studies
showed poorly differentiated HCC in 24 cases and well
differentiated HCC in the other 16 cases. The median interval
between initial HR and SLT was 35 months (1–63 months).
Among the 36 patients, 15 had received radiofrequency ablation
or ethanol injection pre-transplantation, 3 patients received
transcatheter arterial chemoembolization (TACE).
Operative parameters and postoperative complications
The operative parameters and post-operative complications
between the two groups of patients were described in Table 2. The
intraoperative blood loss (15606670 ml versus 11806910 ml,
P,0.05) and transfusion volume (10606780 ml versus
8206910 ml, P,0.05) were larger in the SLT group than in
PLTW group. The operation time was longer in the SLT versus
PLTW group (340677 min versus 302681 min, P,0.05). These
indicated that SLT would increase the operation difficulties.
However, the postoperative recovery and intraoperative complications between the two groups were not significantly different
(P.0.05).
Patient survival
There were 11 deaths in the SLT group, including 1
perioperative death due to severe infection. In PLTW group,
there were 36 deaths, including 3 perioperative deaths (1 died
from renal failure, 1 from severe infection and 1 from hepatic
artery thrombosis). Survival curves generated by the KaplanMeier method are shown in Figure 1A. Log-Rank test showed that
the patient survival was not significantly different between the two
groups (x2= 0.926, P = 0.336).
And in those patients undergoing primary OLT for HCC
beyond Milan criteria, there were 75 deaths including 7
perioperative deaths (3 from severe infection, 2 from renal failure,
1 from GVHD and 1 from biliary ischemia). Compared with this
Figure 2. (A) shows the cumulative recurrence rate between SLT group and PLTW group, a Log-Rank test showed P = 0.525. (B) shows the cumulative
recurrence rate between SLT group and PLTB group, a Log-Rank test showed P = 0.006. Abbreviation: SLT salvage liver transplantation, PLTW primary
liver transplantation within Milan criteria, PLTB primary liver transplantation beyond Milan criteria.
doi:10.1371/journal.pone.0041820.g002
Table 3. Survival and tumor recurrence rate.
Group Cases
Follow-up
(month) Recurrence Overall survival rate (%) Tumor-free survival rate (%)
Rate time (month) 1 yr 3 yrs 5 yrs 1 yrs 3 yrs 5 yrs
SLT 36 58.7620.7 5/36 28.2615.1 97.2 80.6 69.4 97.1 87.9 74.2
PLTW 147 64.2618.1 15/147 30.4611.8 98.0 86.4 75.5 97.9 89.9 80.3
PLTB 156 57.2633.1 63/156 22.5614.9 96.2 64.7 48.7 88.5 53.2 33.6
P value 0.065 ,0.001 ,0.001 0.657 ,0.001 ,0.001 0.002 ,0.001 ,0.001
Abbreviation: SLT, salvage liver transplantation; PLTW, primary liver transplantation for HCC within Milan criteria; PLTB, primary liver transplantation for HCC beyond
Milan criteria.
doi:10.1371/journal.pone.0041820.t003
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41820

group of patients, patients in SLT group achieved longer survival
(P,0.05) (Figure 1B).
Tumor recurrence and risk factors
By December 2010, all the patients were follow-up 25–83
months. The median follow-up time of SLT group was 61 months.
Five patients of the SLT group experienced recurrences during
follow-up, with the mean recurrence time of 28.2615.1 months.
Two patients had metastases in the lung, and the other 3 in the
liver graft, bone and brain, respectively. While in the PLTW
group, the median follow-up time was 62 months, 15 patients
experienced recurrences in 30.4611.8 months, which were also
Table 4. Risk factors for Overall survival of liver transplantation by Multivariate Analysis.
Items n Mean±SD (months) Univariate analysis Multivariate analysis
Age (yr) 0.192
,47 169 63.2162.23
$47 170 59.2363.41
Gender (M/F) 0.241
Male 251 57.3462.16
Female 78 59.5463.31
HBV infeciont 0.105
Present 328 58.9462.16
Absent 11 62.5465.31
HCV infection 0.143
Present 22 59.2462.16
Absent 317 61.5463.31
ALT 0.267
,135 169 63.5262.34
$135 170 58.1263.64
MELD score 0.228
,18 169 66.2164.43
$18 170 62.0365.22
Liver cirrhosis 0.312
Present 271 55.3462.16
Absent 68 59.5463.31
Nodules numbers 0.109
#3 227 65.5261.54
.3 62 59.1262.75
AFP levels 0.001 0.031a
,400 66 73.6662.09
$400 273 62.0961.64
Macrovascular invasion ,0.001 ,0.001b
Present 37 40.2864.16
Absent 302 67.2262.35
Microvascular invasion ,0.001 0.009c
Present 71 46.5663.46
Absent 268 69.3163.45
Pathologic characteristics 0.092
Poor differentiated 106 62.3461.46
Well differentiated 233 59.8663.17
Pre-transplant treatment 0.185
Present 164 62.5463.46
Absent 175 59.9164.32
a
Relative risk:1.91, 95% CI: 1.04–3.02.
b
Relative risk:3.33, 95% CI: 1.77–6.24.
c
Relative risk:2.93, 95% CI: 1.31–6.11.
Cox Proportional Hazards model showed that vascular invasion, including macrovascular and microvascular invasion, as well as AFP level .400 IU/L were risk factors for
tumor recurrence after OLT.
doi:10.1371/journal.pone.0041820.t004
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41820

found in lungs (8 cases), liver grafts (5 cases) and bone (2 cases).
The recurrence time (P.0.05) and recurrence rate (13.9% versus
10.2%, x2= 0.403, P.0.05) were comparable between the two
groups. The tumor recurrence profiles of the patients in the two
groups are shown in Table 3. The cumulative recurrence rate
curves are shown in Figure 2A.
In 156 patients who received primary OLT for HCC beyond
Milan criteria, 63 (40.3%) patients experienced recurrence in
16.5610.9 months. The recurrence rate was higher in this group
of patients compared with SLT group (x2= 8.977, P = 0.003). The
cumulative recurrence rate curves are shown in Figure 2B.
A Cox Proportional Hazards model was made to evaluate the
risks factors for tumor recurrence in all of the patients here, the
result showed that vascular invasion, including macrovascular and
microvascular invasion, as well as AFP level .400 IU/L were risk
factors for tumor recurrence after LT, as showed in Table 4.
Discussion
HCC is one of the most common malignant tumors in China,
with the incidence rate up to 80 per million populations. More
than 80% patients had simultaneous liver cirrhosis, which leads to
an actual rate of resection less than 30%, while the 5 year
recurrence rate after resection reached above 70% [3,5,6].
Theoretically, OLT was the most effective treatment for HCC
patients, which not only achieves radical tumor resection, but also
deals with the frequently concurrent end stage liver diseases. In
China mainland, nearly half of liver transplant recipients were
patients with HCC [7]. However, considering the severe organ
shortage, high cost and perioperative risk of this procedure, as well
as constraint in concept, HR remains to be the mainstay treatment
for patients with resectable early HCC. Although OLT can yield a
higher tumor-free survival than HR in early HCC patients with
Child A stage liver function, the 5-year survival rate had no
significant difference between the two procedures [8]. The reasons
might be as follows: (1) the perioperative mortality of liver
transplant is higher than that of HR; (2) the survival rate of liver
transplant recipients declines because of rejection, recurrence of
hepatitis, side effects of immunosuppressants and transplantrelated complications; (3) re-excision, radiofrequency ablation and
OLT can be applied for recurrence after HR, which prolong
patient survival time; (4) due to organ shortage, 15%,33% of
patients lost the opportunities of transplantation because of tumor
progression [7,9,10].
However, SLT remained a life-saving treatment for patients
with intrahepatic recurrence or liver function deterioration after
primary HR [2,10,11]. In some cases, surgical resection can be
taken as an initial treatment so as to control tumor progression
when patients are on the waiting list. Transplantation can be
implemented as soon as donor liver is available [12]. Previous
studies have documented that 80% of patients suffered from
intrahepatic recurrence after HR, and about 52% of the recurrent
patients are still transplantable [13,14,15]. Whether the patients
can receive SLT depends on the tumor factors, age of patients, the
time waiting for a donor liver, and the patients’ willingness.
The surgical difficulty in SLT increases due to peritoneal
adhesions caused by previous upper abdominal surgery. The
adhesions usually lie between the cut surface and the omentum
and/or the intestine. In addition, some recipients may have
vigorous portal collaterals, which might lead to massive intraoperative bleeding. The dissection of the liver hilum might be
another technical difficulty in SLT, especially when hilar
dissection has been done extensively during previous hepatectomy.
Several such cases were included in our study, we used the iliac
artery from the same donor as a bridge and the celiac trunk of the
graft was anastomosed to the recipients’ abdominal aorta via the
bridge. A Roux-en-Y hepaticojejunostomy was utilized for biliary
reconstruction. Although some studies have shown that SLT does
not increase the difficulty of surgery [13,16,17], the SLT group did
have longer operative time, more introperative blood loss and
transfusion volume in our study. The interval between initial LR
and SLT may be a factor related to the operative difficulty since
the severity of adhesion is associated with this interval. However,
the increased difficulty neither increases the post-operative
complications, nor negatively affects the short and long term
prognosis. There was one patient received SLT just 1 month after
resection, the later was performed in another hospital. This patient
had liver cirrhosis and a tumor with 5 cm in diameter locating at
the right lobe, while two susceptive small nodules in S4 was also
noted, which was regarded as cirrhotic nodules by the doctors.
During the first operation, the cirrhosis was more severe than what
had been expected before the operation, right lobectomy was
performed. Importantly, a PET-CT scanning one month after the
resection revealed that the two nodules in S4 were HCC nodules.
Therefore, LT was suggested immediately after the PET-CT
scanning. This patient seems more likely had remnant cancer, and
he had tumor recurrence about 24 months after transplantation.
Nowadays, the treatment for liver cancer develops rapidly.
There are a variety of interventional therapy that can be chosen
for recurrence, including radiofrequency ablation, ethanol injection, and TACE. Besides, some studies [14] have shown that SLT
has no obvious advantage over the treatment strategies mentioned
above. However, most studies still support that transplantation is
the most effective treatment for HCC. In this study, we observe
that the Milan criteria are still eligible for the 36 patients at the
time of recurrence. And the 5-year overall survival rate and
disease-free survival rate are not lower than those undergoing
primary OLT.
In conclusion, in comparison with primary OLT, although SLT
would increase the operation difficulties, it provides a good option
for patients with HCC recurrence after curative resection.
Identification of recurrent patients who would gain favorable
outcomes from SLT will help decision-making among multiple
choices of treatment.
Author Contributions
Conceived and designed the experiments: LW ZG XH. Performed the
experiments: LW AH NT JZ ML. Analyzed the data: AH NT JZ.
Contributed reagents/materials/analysis tools: LW ZG XH. Wrote the
paper: LW NT ZG.
References
1. Venook AP, Papandreou C, Furuse J, de Guevara LL (2010) The incidence and
Epidemiology of Hepatocellular Carcinoma: A global and Regional perspective.
The Oncologist 15: 5–13.
2. Majno PE, Sarasin FP, Mentha G, Hadenque A (2000) Primary Liver
Resection and Salvage Transplantation or Primary Liver Transplantation in
Patients With Single, Small Hepatocellular Carcinoma and Preserved Liver
Function: An Outcome-Oriented Decision Analysis. Hepatology 31: 899–
906.
3. Fong Y, Sun RL, Jarnagin W, Blumqart LH (1999) An analysis of 412 cases of
hepatocellular carcinoma at a Western center. Ann Surg 229: 190–800.
4. Wu YM, Voigt M, Rayhill S, Katz D, Chenhsu RY, et al. (2001) Suprahepatic
venacavaplasty (cavaplasty) with retrohepatic vava extension in liver transplantation: experience with first 115 cases. Transplantation 72: 1389–1394.
5. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, et al. (2001) Improving survival
results after resection of hepatocellular carcinoma: a prospective study of 377
patients over 10 years. Ann Surg 234: 63–70.
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41820

6. Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, et al. (2003) Liver
resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate
analysis of risk factors for intrahepatic recurrence. Ann Surg 237: 536–543.
7. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, et al. (2008) Liver
Transplantation for Hepatocellular Carcinoma. Ann Surg Oncol 15: 1001–
1007.
8. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, et al. (2001)
Vascular invasion and histopathologic grading determine outcome after liver
transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33: 1080–
1086.
9. Facciuto ME, Koneru B, Rocca JP, Wolf DC, Kim-Schluger L, et al. (2008)
Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of
liver resection salvage transplantation, and primary liver transplantation. Ann
Surg Oncol 15: 1383.
10. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, et al. (2004) High pathological
risk of recurrence after surgical resection for hepatocellular carcinoma: An
indication for salvage liver transplantation. Liver Transplantation 10: 1294–
1300.
11. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, et al. (2003) Liver
resection as a bridge to transplantation for hepatocellular carcinoma on
cirrhosis: a reasonable strategy? Ann Surg 238: 508.
12. Kim BW, Park YK, Kim YB, Wang HJ, Kim MW, et al. (2008) Salvage liver
transplantation for recurrent hepatocellular carcinoma after liver resection:
feasibility of the Milan criteria and operative risk. Transplant Proc 40: 3558–
3561.
13. Hu RH, Ho MC, Wu YM, Yu SC, Lee PH, et al. (2005) Feasibility of salvage
liver transplantation for patients with recurrent hepatocellular carcinoma. Clin
Transplant 19: 175–180.
14. Poon RT, Fan ST, Wong J (2000) Risk factors, prevention and management of
postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg
232: 10–24.
15. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and
pattern of recurrence after resection of small hepatocellular carcinoma in
patients with preserved liver function: implication for a strategy of salvage
transplantation. Ann Surg 235: 373–382.
16. Cucchetti A, Vitale A, Gaudio MD, Ravaioli M, Ercolani G, et al. (2010) Harm
and benefits of primary liver resection and salvage transplantation for
hepatocellular carcinoma. American Journal of Transplantation 10:619–627.
17. Eguchi S, Hidaka M, Tomonage T, Miyazaki K, Inoluma T, et al. (2009) Actual
therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and
its impact on survival after salvage living donor liver transplantation.
J Gastroenterol 44: 624–629.
Salvage Liver Transplantation for Recurrent HCC
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41820

